Latest news with #Qbtech
Business Wire
4 days ago
- Business
- Business Wire
Qbtech Expands US Presence with Formation of New Houston-Based Teams and Staff Appointments
HOUSTON--(BUSINESS WIRE)-- Qbtech, the global leader in objective ADHD testing, announces the formation of its Houston-based clinical research and strategic partnership teams, along with new staff appointments and promotions at the company's US headquarters. The employee expansions bolster the company's continued growth in the region, enhancing its capabilities and market presence as it continues to develop and enhance its software solutions. Former clinical research manager Ragini Sanyal has been promoted to Head of Clinical Research, with Jonas Bäckström joining as Chief Strategic Partnership Officer and Jack Smith as Head of US Commercial Operations. As Head of Clinical Research, Sanyal will lead the formalized clinical research team and its efforts to study the clinical utility and validity of objective ADHD assessments for diagnosing ADHD and its benefits in post-treatment follow-up. 'I truly believe objective ADHD technology is a guiding light through the uncertainty of the mental health space. I'm so excited to take on this role and lead our newly structured clinical research team to curate and share the data behind our objective assessments and how they can be used to progress ADHD care,' says Sanyal. 'This new team structure allows us to streamline our efforts across clinical operations, data management, medical writing, and trial execution. It will also help simplify decision-making, improve cross-functional collaboration, and provide a clearer focus as we continue to expand both our team and our portfolio. Coming off the World Congress on ADHD, I am so proud that our team was able to present four meaningful posters, and I can only imagine what we will accomplish in the coming months and years.' Jonas Bäckström, a former member of Qbtech's Board of Directors, has joined as Chief Strategic Partnership Officer, leading the newly established partnerships department from the Houston office. He brings a strong background in digital innovation, having worked with a pioneering digital healthcare provider in Sweden prior to joining Qbtech. 'This is an exciting opportunity for both me and Qbtech,' says Bäckström. 'I look forward to focusing on building scalable, evidence-based business models in the ADHD space and linking telehealth innovation with clinical, payer, and employer ecosystems. With my experience in business development and digital health, I am eager to help our partners achieve sustainable growth, improve patient outcomes, and shape a smarter, more accountable future for mental health, starting with ADHD.' Jack Smith will serve as Head of US Commercial Operations, leading efforts across sales and clinical support to drive Qbtech's expansion and identify new growth opportunities. A military veteran, Smith has served in various roles within the healthcare industry for more than 25 years. "I'm thrilled to be joining Qbtech at such a pivotal time in the US ADHD market. My goal is to build a world-class sales team that delivers real value to clinicians by driving improved patient outcomes through objective, evidence-based tools,' says Smith. 'As awareness grows and underserved markets expand, we have a unique opportunity to empower physicians with the confidence they need to make accurate ADHD diagnoses." The Qbtech team plans to hire additional staff in the Houston office throughout the year. Available career opportunities can be found at Qbtech is a privately-owned Swedish company that has developed leading solutions and products for improving the identification, diagnosis, treatment, and follow-up of patients living with ADHD. Qbtech has operations in 14 countries and has offices in Stockholm, Houston, and London. Qbtech is an award-winning company recognized for its innovation, most recently winning the 2022 HSJ Partnership Award for the 'Best Mental Health Partnership with the NHS.' For more information about Qbtech, visit
Yahoo
4 days ago
- Business
- Yahoo
Qbtech Expands US Presence with Formation of New Houston-Based Teams and Staff Appointments
Addition of clinical research and strategic partnership teams marks another milestone for Qbtech in North America, bolstering the company's regional capabilities and footprint HOUSTON, June 02, 2025--(BUSINESS WIRE)--Qbtech, the global leader in objective ADHD testing, announces the formation of its Houston-based clinical research and strategic partnership teams, along with new staff appointments and promotions at the company's US headquarters. The employee expansions bolster the company's continued growth in the region, enhancing its capabilities and market presence as it continues to develop and enhance its software solutions. Former clinical research manager Ragini Sanyal has been promoted to Head of Clinical Research, with Jonas Bäckström joining as Chief Strategic Partnership Officer and Jack Smith as Head of US Commercial Operations. As Head of Clinical Research, Sanyal will lead the formalized clinical research team and its efforts to study the clinical utility and validity of objective ADHD assessments for diagnosing ADHD and its benefits in post-treatment follow-up. "I truly believe objective ADHD technology is a guiding light through the uncertainty of the mental health space. I'm so excited to take on this role and lead our newly structured clinical research team to curate and share the data behind our objective assessments and how they can be used to progress ADHD care," says Sanyal. "This new team structure allows us to streamline our efforts across clinical operations, data management, medical writing, and trial execution. It will also help simplify decision-making, improve cross-functional collaboration, and provide a clearer focus as we continue to expand both our team and our portfolio. Coming off the World Congress on ADHD, I am so proud that our team was able to present four meaningful posters, and I can only imagine what we will accomplish in the coming months and years." Jonas Bäckström, a former member of Qbtech's Board of Directors, has joined as Chief Strategic Partnership Officer, leading the newly established partnerships department from the Houston office. He brings a strong background in digital innovation, having worked with a pioneering digital healthcare provider in Sweden prior to joining Qbtech. "This is an exciting opportunity for both me and Qbtech," says Bäckström. "I look forward to focusing on building scalable, evidence-based business models in the ADHD space and linking telehealth innovation with clinical, payer, and employer ecosystems. With my experience in business development and digital health, I am eager to help our partners achieve sustainable growth, improve patient outcomes, and shape a smarter, more accountable future for mental health, starting with ADHD." Jack Smith will serve as Head of US Commercial Operations, leading efforts across sales and clinical support to drive Qbtech's expansion and identify new growth opportunities. A military veteran, Smith has served in various roles within the healthcare industry for more than 25 years. "I'm thrilled to be joining Qbtech at such a pivotal time in the US ADHD market. My goal is to build a world-class sales team that delivers real value to clinicians by driving improved patient outcomes through objective, evidence-based tools," says Smith. "As awareness grows and underserved markets expand, we have a unique opportunity to empower physicians with the confidence they need to make accurate ADHD diagnoses." The Qbtech team plans to hire additional staff in the Houston office throughout the year. Available career opportunities can be found at About Qbtech Founded in 2002, Qbtech is a privately-owned Swedish company that has developed leading solutions and products for improving the identification, diagnosis, treatment, and follow-up of patients living with ADHD. Qbtech has operations in 14 countries and has offices in Stockholm, Houston, and London. Qbtech is an award-winning company recognized for its innovation, most recently winning the 2022 HSJ Partnership Award for the 'Best Mental Health Partnership with the NHS.' For more information about Qbtech, visit View source version on Contacts Media Contact: Hilari Barton, Trevelino/KellerHnbarton@ 404-214-0722 x 130
Associated Press
10-05-2025
- Health
- Associated Press
New Study from UK's Largest Virtual ADHD Service Validates Role of Objective Testing in Delivering Personalized, High-Quality Remote ADHD Care
LONDON & PRAGUE--(BUSINESS WIRE)--May 10, 2025-- As demand for virtual ADHD care increases, findings from a new study conducted with ADHD 360, the UK's largest evidence-based digital service specializing in ADHD diagnosis and treatment, reveal how objective ADHD diagnostic and monitoring technology improves patient outcomes and clinical certainty. Presented at the 2025 ADHD World Congress in Prague, Czech Republic, the findings highlight the role of QbCheck, Qbtech's remote testing solution, in enabling clinicians to make more confident, data-informed decisions, supporting a more personalized and collaborative care model. The tool allows for greater clarity when assessing symptoms and adjusting treatment plans over time, ensuring diagnostic accuracy and helping to improve alignment between clinicians and patients throughout the care journey. The results from ADHD 360's implementation of this model showcase how a standardized approach to virtual ADHD care improves clinician confidence, reduces wait times, and enhances patient engagement. In addition to its use as a diagnostic tool, QbCheck, the remote objective assessment tool from Qbtech, was used to monitor treatment effects, helping clinicians adjust treatment as needed. 'Consistency and quality are at the heart of our virtual care model, and QbCheck plays a key role in upholding these standards,' says Carl Ellis, Mental Health Nurse and Team Manager, ADHD 360. 'The objective data it provides ensures that every patient is assessed using the same evidence-based criteria, regardless of where they are. Not only does this minimize the risk of subjective bias, but it also ensures that our clinical team can deliver reliable, high-quality care at scale.' The results showed significant improvement from the baseline to post-treatment assessments. Beyond QbCheck's value as an objective symptom measurement and diagnostic tool, the data highlights patient response to pharmacological treatment, which can support clinicians in developing individualized and adaptive treatment plans, providing quantifiable data on symptom presentation and response. In this study, data was collected from routine QbCheck assessments completed as part of the ADHD 360 model in the United Kingdom. Baseline data was collected prior to diagnosis and treatment, with additional QbCheck assessments administered after patients were optimized with stimulant medication treatment. In addition to QbCheck, all patients were given the Adult ADHD Self Report Scale (ASRS) or the Swanson, Nolan and Pelham Rating Scale (SNAP) and QbCheck Rating Scale (QbRS) to assess self-reported symptoms. 'QbCheck brings transparency and structure to the process, enabling clinicians to clearly visualize symptoms, track treatment response, and give patients the objective validation they deserve,' says Dr. Mikkel Hansen, Chief Medical Officer, Qbtech. 'This data shows how a standardized pathway to virtual ADHD care helps clinicians successfully facilitate remote monitoring of medication treatment effects, symptom regulation, and overall treatment outcomes, which are essential to virtual care models like ADHD 360.' With increased scrutiny around ADHD care and virtual care models expanding, QbCheck stands out for its clinical rigor, patient-centered design and scalability. First developed in 2016, QbCheck enriches the clinician and patient experience to ensure optimal care in virtual settings. QbCheck is used by more than 10,000 clinicians worldwide operating virtual clinics and those with brick-and-mortar locations who offer remote ADHD services. Its flexibility for these clinicians and their patients is key to providing equitable access to care regardless of location, especially those who live in a mental health provider shortage area. Since its launch in Sweden in 2002, Qbtech has supported more than 1 million patients globally. More than 40 independent studies document the company's benefits across the patient care pathway, including improved access to care, elevated clinician confidence, a 50% better indication of treatment effects than standardized self-rating scales, and consistency of care across multiple disciplines. Visit to learn more. About Qbtech Founded in 2002, Qbtech is a privately-owned Swedish company that has developed leading solutions and products for improving the identification, diagnosis, treatment, and follow-up of patients living with ADHD. Qbtech has operations in 14 countries and has offices in Stockholm, Houston, and London. Qbtech is an award-winning company recognized for its innovation, most recently winning the 2022 HSJ Partnership Award for the 'Best Mental Health Partnership with the NHS.' For more information about Qbtech, visit View source version on CONTACT: Media Contact: Hilari Barton, Trevelino/Keller [email protected] 404-214-0722 x 130 KEYWORD: NORTH AMERICA UNITED STATES UNITED KINGDOM EUROPE CZECH REPUBLIC TEXAS INDUSTRY KEYWORD: TECHNOLOGY MENTAL HEALTH OTHER TECHNOLOGY HEALTH TECHNOLOGY SOFTWARE OTHER HEALTH HEALTH GENERAL HEALTH DATA MANAGEMENT SOURCE: Qbtech Copyright Business Wire 2025. PUB: 05/10/2025 06:45 AM/DISC: 05/10/2025 06:46 AM
Yahoo
10-05-2025
- Health
- Yahoo
New Study from UK's Largest Virtual ADHD Service Validates Role of Objective Testing in Delivering Personalized, High-Quality Remote ADHD Care
Data presented at ADHD World Congress highlights how QbCheck supports diagnostic accuracy and individualized treatment monitoring, enabling efficient and robust care in virtual settings. News Summary: New findings show significant improvements in access, clinician confidence, symptom tracking, and individualized care using objective testing. The study underscores the importance of scalable, evidence-based tools, as many countries, including both the UK and the US, face rising demand for ADHD diagnosis and treatment. The study revealed significant improvements post-treatment, validating clinical practice and better clinician-patient alignment. LONDON & PRAGUE, May 10, 2025--(BUSINESS WIRE)--As demand for virtual ADHD care increases, findings from a new study conducted with ADHD 360, the UK's largest evidence-based digital service specializing in ADHD diagnosis and treatment, reveal how objective ADHD diagnostic and monitoring technology improves patient outcomes and clinical certainty. Presented at the 2025 ADHD World Congress in Prague, Czech Republic, the findings highlight the role of QbCheck, Qbtech's remote testing solution, in enabling clinicians to make more confident, data-informed decisions, supporting a more personalized and collaborative care model. The tool allows for greater clarity when assessing symptoms and adjusting treatment plans over time, ensuring diagnostic accuracy and helping to improve alignment between clinicians and patients throughout the care journey. The results from ADHD 360's implementation of this model showcase how a standardized approach to virtual ADHD care improves clinician confidence, reduces wait times, and enhances patient engagement. In addition to its use as a diagnostic tool, QbCheck, the remote objective assessment tool from Qbtech, was used to monitor treatment effects, helping clinicians adjust treatment as needed. "Consistency and quality are at the heart of our virtual care model, and QbCheck plays a key role in upholding these standards," says Carl Ellis, Mental Health Nurse and Team Manager, ADHD 360. "The objective data it provides ensures that every patient is assessed using the same evidence-based criteria, regardless of where they are. Not only does this minimize the risk of subjective bias, but it also ensures that our clinical team can deliver reliable, high-quality care at scale." The results showed significant improvement from the baseline to post-treatment assessments. Beyond QbCheck's value as an objective symptom measurement and diagnostic tool, the data highlights patient response to pharmacological treatment, which can support clinicians in developing individualized and adaptive treatment plans, providing quantifiable data on symptom presentation and response. In this study, data was collected from routine QbCheck assessments completed as part of the ADHD 360 model in the United Kingdom. Baseline data was collected prior to diagnosis and treatment, with additional QbCheck assessments administered after patients were optimized with stimulant medication treatment. In addition to QbCheck, all patients were given the Adult ADHD Self Report Scale (ASRS) or the Swanson, Nolan and Pelham Rating Scale (SNAP) and QbCheck Rating Scale (QbRS) to assess self-reported symptoms. "QbCheck brings transparency and structure to the process, enabling clinicians to clearly visualize symptoms, track treatment response, and give patients the objective validation they deserve," says Dr. Mikkel Hansen, Chief Medical Officer, Qbtech. "This data shows how a standardized pathway to virtual ADHD care helps clinicians successfully facilitate remote monitoring of medication treatment effects, symptom regulation, and overall treatment outcomes, which are essential to virtual care models like ADHD 360." With increased scrutiny around ADHD care and virtual care models expanding, QbCheck stands out for its clinical rigor, patient-centered design and scalability. First developed in 2016, QbCheck enriches the clinician and patient experience to ensure optimal care in virtual settings. QbCheck is used by more than 10,000 clinicians worldwide operating virtual clinics and those with brick-and-mortar locations who offer remote ADHD services. Its flexibility for these clinicians and their patients is key to providing equitable access to care regardless of location, especially those who live in a mental health provider shortage area. Since its launch in Sweden in 2002, Qbtech has supported more than 1 million patients globally. More than 40 independent studies document the company's benefits across the patient care pathway, including improved access to care, elevated clinician confidence, a 50% better indication of treatment effects than standardized self-rating scales, and consistency of care across multiple disciplines. Visit to learn more. About Qbtech Founded in 2002, Qbtech is a privately-owned Swedish company that has developed leading solutions and products for improving the identification, diagnosis, treatment, and follow-up of patients living with ADHD. Qbtech has operations in 14 countries and has offices in Stockholm, Houston, and London. Qbtech is an award-winning company recognized for its innovation, most recently winning the 2022 HSJ Partnership Award for the 'Best Mental Health Partnership with the NHS.' For more information about Qbtech, visit View source version on Contacts Media Contact: Hilari Barton, Trevelino/KellerHnbarton@ 404-214-0722 x 130
Business Wire
10-05-2025
- Health
- Business Wire
New Study from UK's Largest Virtual ADHD Service Validates Role of Objective Testing in Delivering Personalized, High-Quality Remote ADHD Care
LONDON & PRAGUE--(BUSINESS WIRE)--As demand for virtual ADHD care increases, findings from a new study conducted with ADHD 360, the UK's largest evidence-based digital service specializing in ADHD diagnosis and treatment, reveal how objective ADHD diagnostic and monitoring technology improves patient outcomes and clinical certainty. Presented at the 2025 ADHD World Congress in Prague, Czech Republic, the findings highlight the role of QbCheck, Qbtech's remote testing solution, in enabling clinicians to make more confident, data-informed decisions, supporting a more personalized and collaborative care model. The tool allows for greater clarity when assessing symptoms and adjusting treatment plans over time, ensuring diagnostic accuracy and helping to improve alignment between clinicians and patients throughout the care journey. The results from ADHD 360's implementation of this model showcase how a standardized approach to virtual ADHD care improves clinician confidence, reduces wait times, and enhances patient engagement. In addition to its use as a diagnostic tool, QbCheck, the remote objective assessment tool from Qbtech, was used to monitor treatment effects, helping clinicians adjust treatment as needed. 'Consistency and quality are at the heart of our virtual care model, and QbCheck plays a key role in upholding these standards,' says Carl Ellis, Mental Health Nurse and Team Manager, ADHD 360. 'The objective data it provides ensures that every patient is assessed using the same evidence-based criteria, regardless of where they are. Not only does this minimize the risk of subjective bias, but it also ensures that our clinical team can deliver reliable, high-quality care at scale.' The results showed significant improvement from the baseline to post-treatment assessments. Beyond QbCheck's value as an objective symptom measurement and diagnostic tool, the data highlights patient response to pharmacological treatment, which can support clinicians in developing individualized and adaptive treatment plans, providing quantifiable data on symptom presentation and response. In this study, data was collected from routine QbCheck assessments completed as part of the ADHD 360 model in the United Kingdom. Baseline data was collected prior to diagnosis and treatment, with additional QbCheck assessments administered after patients were optimized with stimulant medication treatment. In addition to QbCheck, all patients were given the Adult ADHD Self Report Scale (ASRS) or the Swanson, Nolan and Pelham Rating Scale (SNAP) and QbCheck Rating Scale (QbRS) to assess self-reported symptoms. 'QbCheck brings transparency and structure to the process, enabling clinicians to clearly visualize symptoms, track treatment response, and give patients the objective validation they deserve,' says Dr. Mikkel Hansen, Chief Medical Officer, Qbtech. 'This data shows how a standardized pathway to virtual ADHD care helps clinicians successfully facilitate remote monitoring of medication treatment effects, symptom regulation, and overall treatment outcomes, which are essential to virtual care models like ADHD 360.' With increased scrutiny around ADHD care and virtual care models expanding, QbCheck stands out for its clinical rigor, patient-centered design and scalability. First developed in 2016, QbCheck enriches the clinician and patient experience to ensure optimal care in virtual settings. QbCheck is used by more than 10,000 clinicians worldwide operating virtual clinics and those with brick-and-mortar locations who offer remote ADHD services. Its flexibility for these clinicians and their patients is key to providing equitable access to care regardless of location, especially those who live in a mental health provider shortage area. Since its launch in Sweden in 2002, Qbtech has supported more than 1 million patients globally. More than 40 independent studies document the company's benefits across the patient care pathway, including improved access to care, elevated clinician confidence, a 50% better indication of treatment effects than standardized self-rating scales, and consistency of care across multiple disciplines. Visit to learn more. Qbtech is a privately-owned Swedish company that has developed leading solutions and products for improving the identification, diagnosis, treatment, and follow-up of patients living with ADHD. Qbtech has operations in 14 countries and has offices in Stockholm, Houston, and London. Qbtech is an award-winning company recognized for its innovation, most recently winning the 2022 HSJ Partnership Award for the 'Best Mental Health Partnership with the NHS.' For more information about Qbtech, visit
